Back
    Get started

    Beta notice: PeptiJournal is currently in beta. Calculator math and RUO research protocol summaries should be independently double-checked against source literature before use in any research workflow.

    §Sexual HealthResearch protocol

    Kisspeptin.

    Kisspeptin (also known as metastin) is a naturally occurring neuroendocrine peptide that plays a pivotal role in human reproduction by stimulating gonadotropin-releasing hormone (GnRH) secretion[1]...

    Last updated:

    Research Use Only. PeptiJournal supports private research documentation and calculation support. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.

    Calculated-volume support unavailable

    This selected cited guide does not contain one unambiguous vial, per-event amount, cadence, and diluent set. No value was inferred from general library metadata. Review the cited table below before creating a private Research Use Only record.

    Cited protocol & reconstitution guide

    Source-backed reference fields by phase, including any volume fields authored in the cited guide.

    Low-dose pulse (once daily SC)

    50-100 mcg

    Units / volume1–2 units (0.01–0.02 mL)

    Standard pulse (once daily SC)

    100-200 mcg

    Units / volume2–4 units (0.02–0.04 mL)

    Split dose (twice daily SC)

    100 mcg

    Units / volume2 units (0.02 mL)

    Overview

    Overview

    Kisspeptin (also known as metastin) is a naturally occurring neuroendocrine peptide that plays a pivotal role in human reproduction by stimulating gonadotropin-releasing hormone (GnRH) secretion[1]. This small peptide binds to the GPR54 receptor in the hypothalamus, triggering pulsatile GnRH release and downstream secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH)[2]. Originally identified as a metastasis-suppressor gene product, kisspeptin has become a major focus in r

    Category
    Sexual Health
    Routes
    subcutaneous

    Mechanism

    Kisspeptin

    Mechanism of action

    Mechanism of action

    Kisspeptin works near the top of the hormone chain. The brain releases kisspeptin, which turns on GnRH. GnRH then tells the pituitary gland to release LH and FSH. In men, LH tells the testes to make testosterone. FSH helps support sperm production. In women, LH and FSH help control ovulation and follicle growth. The main receptor is called GPR54, also called KISS1R. A receptor is like a lock on a cell. Kisspeptin is the key that turns that lock. When this signal works, the body can send a stronger LH and FSH message. When this pathway is broken, puberty and fertility signals can fail. For testosterone research, the key point is simple: kisspeptin does not replace testosterone. It tries to make the body send more LH first. If the testes can respond to LH, testosterone may rise. If the pituitary or testes cannot respond, kisspeptin is unlikely to fix that problem.

    Key research findings
    • 01

      Kisspeptin/KISS1R (GPR54) signaling is an upstream activator of the hypothalamic-pituitary-gonadal (HPG) axis, stimulating GnRH neurons and downstream luteinizing hormone (LH)/follicle-stimulating hormone (FSH) secretion (animal models and controlled human studies; reviewed by Comninos & Dhillo, Neuroendocrinology, 2017).

    • 02

      Human genetic studies in 2003 linked loss-of-function variants in the kisspeptin receptor (KISS1R/GPR54) to idiopathic hypogonadotropic hypogonadism, establishing the receptor's role in reproductive-axis activation (human genetic studies; reported independently by Seminara et al. and by de Roux et al.).

    • 03

      Controlled human administration studies (notably the Imperial College London group) have characterized acute kisspeptin effects on reproductive hormone release in men and women (human studies).

    • 04

      Functional MRI research in humans has associated kisspeptin administration with activity in brain regions involved in sexual and emotional processing, pointing to proposed roles beyond the HPG axis (human study; Comninos, Dhillo and colleagues).

    • 05

      The KISS1 gene was originally identified as a metastasis-suppressor gene, and preclinical in vitro and animal work continues to map KISS1/KISS1R signaling across species (in vitro and animal models).

    Primary source: IVF oocyte maturation trigger (kisspeptin-54): IVF studies used kisspeptin-54 to help eggs mature before collection. In these studies, kisspeptin-54 triggered egg maturation and may have lowered OHSS risk compared with hCG. OHSS is ovarian hyperstimulation syndrome, a serious IVF complication. Hypoactive sexual desire disorder (HSDD): HSDD means low sexual desire that causes distress. In small men and women studies, IV kisspeptin-54 changed sexual brain response and some arousal measures compared with placebo. Hypothalamic amenorrhea: Hypothalamic amenorrhea means missing periods because the brain is not sending enough hormone signal. Subcutaneous kisspeptin-54 has helped restore LH pulses in this setting, but repeated dosing can make the response fade. Direct HPG-axis pharmacology in healthy adults: Direct head-to-head studies compared IV kisspeptin-10, IV kisspeptin-54, and IV GnRH in healthy men. GnRH raised LH more strongly, while kisspeptin-10 and kisspeptin-54 produced similar short-term LH responses. Testosterone effect in men: In one healthy-men study, longer kisspeptin-10 infusion raised LH and also raised testosterone. Shorter 75-minute kisspeptin-54 studies raised LH/FSH but did not show a testosterone rise during that short window. What has not been done: There is no completed Phase 3 trial, no FDA-approved kisspeptin product, and no strong long-term safety dataset. Claims about testosterone optimization, PCT, or long-term hormone support are still extrapolations.

    Researched Effects

    Researched benefits

    Areas of active research and investigation. Results may vary and are based on preclinical or early clinical data.

    ✨

    & Applications

    ✨

    Research on kisspeptin has revealed multiple potential benefits for reproductive health.

    ✨

    Physiological Sex Hormone Stimulation: Increases endogenous testosterone and estrogen levels by amplifying the body’s own LH/FSH signals without suppressing the HPG axis[11].

    ✨

    Fertility Restoration: Shows promise in functional hypothalamic amenorrhea by rekindling GnRH/LH pulsatility and resuming menstrual cycles[12].

    ✨

    IVF Ovulation Trigger: Can induce robust LH surge to mature oocytes while potentially lowering the risk of ovarian hyperstimulation syndrome compared to traditional hCG triggers[13][14].

    Protocol Reference

    Protocol reference

    Research Use Only. PeptiJournal supports private research documentation and calculation support. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.
    subcutaneous

    Commonly cited research range: 100–200 mcg, daily.

    Reference figures reported in the research literature — not a dosing recommendation. For interactive vial math and scheduling, see the Calculator and Schedule tabs.

    Cited protocol & reconstitution guide

    Source-backed reference fields by phase, including any volume fields authored in the cited guide.

    Low-dose pulse (once daily SC)

    50-100 mcg

    Units / volume1–2 units (0.01–0.02 mL)

    Standard pulse (once daily SC)

    100-200 mcg

    Units / volume2–4 units (0.02–0.04 mL)

    Split dose (twice daily SC)

    100 mcg

    Units / volume2 units (0.02 mL)

    Titration protocol

    1. Low-dose pulseStart
      50-100 mcg once daily SC

      Subcutaneous means under the skin. Often timed before sleep in research-use planning. Rotate injection sites.

    2. Standard pulseBuild
      100-200 mcg once daily SC

      Hold at or below 200 mcg in a single daily dose. Rotate injection sites.

    3. Split doseBuild
      100 mcg twice daily SC

      Split into two subcutaneous injections per day, spaced across the day. Each injection is a separate 100 mcg draw.

    4. Short pulse cycle: 2-4 weeks active / 2-4 weeks offBuild
      Per dosing range above

      Hold 2-4 weeks off between active blocks.

    5. Standard cycle: 4-6 weeks active / 4 weeks offBuild
      Per dosing range above

      Hold 4 weeks off after each active block. Avoid continuous uninterrupted use.

    6. Diagnostic single use: single dose, off period N/AMaintenance
      Per dosing range above

      Single dose only; no off period applies.

    Storage & Handling

    Storage requirements(typical for most peptides)

    ❄️
    Lyophilized (powder)
    -20°C (frozen)

    Can be stored for extended periods. Protect from moisture.

    🧊
    Reconstituted
    2-8°C (refrigerated)

    Store in refrigerator door. Never freeze after reconstitution.

    ⏱️
    Stability window
    28-30 days after reconstitution

    Label vials with reconstitution date. Discard if cloudy.

    Reconstitution steps

    1. 01🌡️Inspect the vial — confirm the label says kisspeptin (with the form noted: -10 or -54), check the mass, and look for any visible cracks or contamination.
    2. 02🧴Draw 2 mL bacteriostatic water into a sterile syringe — this 10 mg vial yields 5 mg/mL.
    3. 03💉Swab both stoppers — wipe the BAC water vial stopper and the kisspeptin vial stopper with a fresh alcohol pad each.
    4. 04💧Add the water slowly down the vial wall — inject slowly, aiming for the side of the vial rather than directly onto the lyophilized powder. This protects the peptide from shear stress.
    5. 05🔄Swirl gently to dissolve — roll or gently swirl the vial. Do not shake. Let it sit until the solution is fully clear.
    6. 06🏷️Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light. Do not freeze reconstituted solution. Use within the supplier's stated beyond-use window when available.
    7. 07❄️Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

    Additional storage notes

    Lyophilized (powder form)

    -4 F (-20 C) long-term — Use supplier label and stability data.

    Reconstituted (liquid form)

    35.6-46.4 F (2-8 C) — Refrigerate immediately after reconstitution; respect supplier beyond-use limits.

    Travel / short-term transport

    Cool, dry, dark — Avoid direct light, freeze-thaw cycles, and elevated temperatures.

    Clinical Evidence

    Clinical evidence

    Extensively studied in reproductive neuroendocrinology, including clinical investigation of gonadotropin and reproductive-axis regulation.

    IVF oocyte maturation trigger (kisspeptin-54): IVF studies used kisspeptin-54 to help eggs mature before collection. In these studies, kisspeptin-54 triggered egg maturation and may have lowered OHSS risk compared with hCG. OHSS is ovarian hyperstimulation syndrome, a serious IVF complication. Hypoactive sexual desire disorder (HSDD): HSDD means low sexual desire that causes distress. In small men and women studies, IV kisspeptin-54 changed sexual brain response and some arousal measures compared with placebo. Hypothalamic amenorrhea: Hypothalamic amenorrhea means missing periods because the brain is not sending enough hormone signal. Subcutaneous kisspeptin-54 has helped restore LH pulses in this setting, but repeated dosing can make the response fade. Direct HPG-axis pharmacology in healthy adults: Direct head-to-head studies compared IV kisspeptin-10, IV kisspeptin-54, and IV GnRH in healthy men. GnRH raised LH more strongly, while kisspeptin-10 and kisspeptin-54 produced similar short-term LH responses. Testosterone effect in men: In one healthy-men study, longer kisspeptin-10 infusion raised LH and also raised testosterone. Shorter 75-minute kisspeptin-54 studies raised LH/FSH but did not show a testosterone rise during that short window. What has not been done: There is no completed Phase 3 trial, no FDA-approved kisspeptin product, and no strong long-term safety dataset. Claims about testosterone optimization, PCT, or long-term hormone support are still extrapolations.

    1. 01Kisspeptin/KISS1R (GPR54) signaling is an upstream activator of the hypothalamic-pituitary-gonadal (HPG) axis, stimulating GnRH neurons and downstream luteinizing hormone (LH)/follicle-stimulating hormone (FSH) secretion (animal models and controlled human studies; reviewed by Comninos & Dhillo, Neuroendocrinology, 2017).
    2. 02Human genetic studies in 2003 linked loss-of-function variants in the kisspeptin receptor (KISS1R/GPR54) to idiopathic hypogonadotropic hypogonadism, establishing the receptor's role in reproductive-axis activation (human genetic studies; reported independently by Seminara et al. and by de Roux et al.).
    3. 03Controlled human administration studies (notably the Imperial College London group) have characterized acute kisspeptin effects on reproductive hormone release in men and women (human studies).
    4. 04Functional MRI research in humans has associated kisspeptin administration with activity in brain regions involved in sexual and emotional processing, pointing to proposed roles beyond the HPG axis (human study; Comninos, Dhillo and colleagues).
    5. 05The KISS1 gene was originally identified as a metastasis-suppressor gene, and preclinical in vitro and animal work continues to map KISS1/KISS1R signaling across species (in vitro and animal models).

    Evidence maturity varies by compound; much peptide research is preclinical (in vitro or animal-model). Where human data are limited, findings should be read as research observations, not clinical conclusions.

    References

    Literature references

    Published research articles and sources related to Kisspeptin.

    1. 01
      Jayasena CN, Abbara A, Comninos AN, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. Journal of Clinical Investigation (2014)
      et al. (2014)
    2. 02
      Abbara A, Jayasena CN, Christopoulos G, et al. Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of OHSS During IVF Therapy. Journal of Clinical Endocrinology & Metabolism (2015)
      et al. (2015)
    3. 03
      Comninos AN, Demetriou L, Wall MB, et al. Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA Network Open (2022)
      et al. (2022)
    4. 04
      Thurston L, Hunjan T, Ertl N, et al. Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA Network Open (2023)
      et al. (2023)
    5. 05
      George JT, Veldhuis JD, Roseweir AK, et al. Kisspeptin-10 Is a Potent Stimulator of LH and Increases Pulse Frequency in Men. Journal of Clinical Endocrinology & Metabolism (2011)
      et al. (2011)
    6. 06
      Narayanaswamy S, Prague JK, Jayasena CN, et al. Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men. Human Reproduction (2015)
      et al. (2015)
    7. 07
      Abbara A, Eng PC, Phylactou M, et al. Kisspeptin: a novel physiological trigger for oocyte maturation in IVF treatment (Lancet 2014 trial). The Lancet (2014)
      et al. (2014)
    8. 08
      Trevisan CM, Montagna E, de Oliveira R, et al. Role of Kisspeptin on Hypothalamic-Pituitary-Gonadal Pathology and Its Effect on Reproduction. PMC review (2021)
      et al. (2021)
    9. 09
      Plant TM The neurobiological mechanism underlying hypothalamic GnRH pulse generation: the role of kisspeptin neurons in the arcuate nucleus. Journal of Endocrinology (2019)
      et al. (2019)
    10. 10
      Hu KL, Chang HM, Zhao HC, et al. The Role of Kisspeptin in the Control of the Hypothalamic-Pituitary-Gonadal Axis and Reproduction. Frontiers in Endocrinology (2022)
      et al. (2022)
    11. 11
      Abbara A, Jayasena CN, Comninos AN, et al. Use of kisspeptin to trigger oocyte maturation during in vitro fertilisation (IVF) treatment. Frontiers in Endocrinology (2022)
      et al. (2022)
    12. 12
      U.S. Food and Drug Administration FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting — Kisspeptin-10 (review against inclusion on 503A Bulks List). FDA (2024)
      et al. (2024)
    13. 13
      U.S. Food and Drug Administration Summary Minutes, October 29, 2024 PCAC Meeting (kisspeptin-10 vote). FDA (2024)
      et al. (2024)
    14. 14
      Skorupskaite K, George JT, Anderson RA The kisspeptin-GnRH pathway in human reproductive health and disease. Journal of Endocrinology (review) (2016)
      et al. (2016)
    15. 15
      George JT, Veldhuis JD, Roseweir AK, et al. Subcutaneous infusion of kisspeptin-54 stimulates gonadotrophin release in women and the response correlates with basal oestradiol levels. Clinical Endocrinology (2017)
      et al. (2017)
    Search PubMed for Kisspeptin

    Observed Effects

    Observed effects in cited research

    Reported effects from clinical and research-context use
    • Mild flushing or warmth shortly after dosing
    • Mild injection-site redness or irritation
    • Transient headache
    • Brief mild nausea
    • Short LH and FSH rise, usually followed by a return toward baseline
    • Possible testosterone rise after longer exposure in men, if the testes respond to LH
    Theoretical and chronic-use risks
    • Signal fade with repeated or nonstop exposure. This is called desensitization or tachyphylaxis.
    • Disruption of normal GnRH pulse timing. GnRH is the brain signal that starts LH and FSH release.
    • Possible heart or blood-vessel concern based on animal data. Human risk is not clear.
    • Unknown effects on hormone-sensitive tissues with long-term exposure.
    • Product quality risk. No kisspeptin product is FDA-approved, and FDA reviewers flagged limited public data on kisspeptin-10 impurities.
    Regulatory safety context
    • In October 2024, an FDA advisory committee voted against adding kisspeptin-10 to the 503A Bulks List. The review pointed to limited safety and effectiveness data, no approved product anywhere in the world, no major pharmacy-standard monograph, signal fade with chronic dosing, and concerning animal findings.

    Research Considerations

    Research considerations

    Research Use Only - not for human or veterinary therapeutic use. Has been studied in clinical research; on this platform it is handled strictly as a research material. Consult a licensed healthcare professional for any clinical decisions.

    • Pregnancy and lactation: Kisspeptin is tied to pregnancy and reproductive cycling. There is no good safety data for use during pregnancy or breastfeeding.
    • Hormone-sensitive cancers: Kisspeptin can affect sex-hormone signaling. That matters for breast, ovarian, or prostate cancer history.
    • Active fertility treatment outside a clinical trial: Do not try to copy an IVF trigger protocol without clinical monitoring. Timing, labs, and ultrasound checks matter.
    • Primary hypogonadism: This means the testes or ovaries are the main problem. Kisspeptin works upstream, so it may not help if the gonads cannot respond.
    • Pituitary disease: Kisspeptin needs a working pituitary gland to raise LH and FSH.
    • Pediatric or adolescent use: Kisspeptin is part of puberty timing. It should not be used casually in children or teens.
    • Heart or vascular concerns: FDA reviewers flagged animal data that may matter for heart and blood-vessel risk. Human relevance is still unclear.

    Factors noted in the research literature; not patient-specific medical advice.

    Regulatory Status

    Regulatory status

    RUO

    Research Use Only. PeptiJournal supports private research documentation and calculation support. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.

    Comparisons

    Comparisons

    CompoundMechanismRouteStatus
    KisspeptinthisA neuroendocrine peptide that activates KISS1R (GPR54) on GnRH neurons to stimulate gonadotropin-releasing hormone secretion, a key upstream regulator of the reproductive axis.subcutaneousInvestigational / RUO
    Melanotan IIA synthetic non-selective melanocortin receptor agonist (including MC1R and MC4R) studied for stimulation of melanogenesis (skin pigmentation) and central melanocortin-mediated activity.subcutaneousInvestigational / RUO
    PT-141A cyclic heptapeptide melanocortin receptor agonist (MC3R/MC4R), an active metabolite of melanotan II, acting on central melanocortin pathways studied for modulation of sexual-response signaling.subcutaneousInvestigational / RUO
    KPVA C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (Lys-Pro-Val) studied for anti-inflammatory activity, proposed to act through intracellular pathways (e.g., NF-kB modulation) without melanocortin pigmentary activity.subcutaneousInvestigational / RUO
    L-CarnitineAn amino acid derivative essential for transporting long-chain fatty acids into mitochondria for beta-oxidation and energy production.subcutaneousInvestigational / RUO
    LivagenA synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Ala) studied for peptidase modulation and epigenetic/chromatin effects (e.g., heterochromatin decondensation) in aging cell models.subcutaneousInvestigational / RUO
    LL-37The sole human cathelicidin-derived cationic antimicrobial peptide (37 residues), studied for broad-spectrum antimicrobial activity, immune modulation, and roles in wound healing and angiogenesis.subcutaneousInvestigational / RUO

    Attributes shown for research comparison only; not a statement of efficacy or therapeutic equivalence.

    FAQ

    Frequently asked questions

    Research-use notice

    Research Use Only. This educational content and calculation support is intended for private research documentation. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.

    Cited guide source: View source

    How these protocol references are compiled·About this library